Human T-lymphotropic virus kind 1 (HTLV-1) provirus expression is especially directed by Tax-responsive components (TRE) inside the lengthy terminal repeats (LTR). Mutations in TRE can cut back provirus expression and since a excessive proviral load (PVL) is a danger issue for the event of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), we evaluated polymorphisms within the 5′ LTR and the affiliation with PVL and illness development.
HTLV-1 LTR and tax sequences derived from asymptomatic carriers (AC) and HAM/TSP sufferers adopted in a longitudinal examine had been analysed based on PVL and medical severity. People contaminated with HTLV-1 presenting the canonical TRE, contemplating pressure ATK-1 because the consensus, displayed sustained larger PVL. In contrast, an LTR A125G mutation in TRE was related to barely diminished PVL solely in HAM/TSP sufferers, though it didn’t affect the pace of illness development.
Furthermore, this polymorphism was frequent in Latin American strains of the HTLV-1 Cosmopolitan Transcontinental subtype. Due to this fact, polymorphisms within the 5′ TRE of HTLV-1 could symbolize one of many components influencing PVL in HAM/TSP sufferers, particularly within the Latin American inhabitants. Certainly, larger PVL within the peripheral blood has been related to an elevated inflammatory exercise within the spinal twine and to a poorer prognosis in HAM/TSP. Nevertheless, this occasion was not related to TRE polymorphisms.
HTLV-1 encephalitis
A 53-year-old lady developed subacute onset of higher limb weak point, sensory loss and cerebellar dysfunction. She was recognized to have human T-lymphotropic virus kind 1 (HTLV-1)-associated myelopathy. MR scan of the mind confirmed intensive T2 hyperintensity inside the deep and subcortical white matter, with punctate distinction enhancement.
Cerebrospinal fluid (CSF) was lymphocytic with very excessive ranges of HTLV-1 provirus in each CSF and peripheral blood lymphocytes. We identified HTLV-1 encephalomyelitis and began high-dose methylprednisolone adopted by a gradual corticosteroid taper. She recovered effectively and regained practical independence within the higher limbs.
Neurological manifestations of HTLV-1 an infection lengthen past classical ‘tropical spastic paraparesis’ and are under-recognised. We assessment the literature on HTLV-1 encephalitis and focus on its prognosis and administration.
HTLV-1 an infection in acute t- lymphocytic leukemia/lymphoma
Grownup T- lymphocyte leukemia/ lymphoma (ATLL), described by Uchiyama et al. in 1977, is a definite neoplasia of peripheral T-lymphocytes attributable to human T-cell lymphotropic virus kind 1 (HTLV-1). The authors describe the case of a 75-year-old feminine affected person who offered with fever, chills, and altered psychological standing.
The peripheral blood morphology confirmed massive atypical lymphocytes with multilobed nuclei and circulate cytometry per ATLL. The authors focus on the pathophysiology, differential prognosis, and subtypes of ATLL along with the diagnostic method utilizing circulate cytometry when bone marrow biopsy is just not accessible and modalities of therapy.
Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated progress suppression in HTLV-1-infected cells
Immunomodulatory imide medication (IMiDs), akin to lenalidomide and pomalidomide, exert pleiotropic results, e.g., antitumor results in a number of myeloma, by binding the protein Cereblon and altering its substrate specificity.
Lenalidomide is authorised for the therapy of grownup T-cell leukemia/lymphoma (ATL) attributable to human T-cell leukemia virus kind 1 (HTLV-1), though the exact mechanisms accountable for its effectiveness haven’t been totally elucidated.
Right here, we used HTLV-1-infected cell traces to research how IMiDs exert anti-ATL results. In three of 4 examined HTLV-1-infected cell traces, the cells handled with lenalidomide or pomalidomide exhibited gentle progress suppression with out apoptosis, which was related to decreased IRF4, c-Myc, and phosphorylated STAT3 ranges in addition to enhanced SOCS3 expression. Moreover, the degrees of enhancer of zeste homolog 2 (EZH2) and trimethyl histone three Lys27 (H3K27me3) had been decreased following IMiD therapy in all three vulnerable cell traces.
An IMiD-mediated discount of EZH2 and H3K27me3 ranges was additionally noticed in a a number of myeloma cell line. Moreover, therapy with an EZH2-inhibitor reproduced the IMiD-mediated results in HTLV-1-infected cells and a number of myeloma cells. These findings strongly recommend {that a} discount of EZH2 expression is concerned within the mechanism underlying the antitumor results of IMiD.
HTLV-2 Encoded Antisense Protein APH-2 Suppresses HIV-1 Replication
Antisense protein of Human T-cell Leukemia Virus Sort 2 (HTLV-2), additionally referred to as APH-2, negatively regulates the HTLV-2 and helps the virus to keep up latency through scheming the transcription. Regardless of the outstanding prevalence of HTLV-2/HIV-1 co-infection, the function of APH-2 influencing HIV-1 replication kinetics is poorly understood and wishes investigation.
On this examine, we investigated the believable function of APH-2 regulating HIV-1 replication. Herein, we report that the overexpression of APH-2 not solely hampered the discharge of HIV-1 pNL4.three from 293T cells in a dose-dependent method but in addition affected the mobile gag expression. The same and constant impact of APH-2 overexpression was additionally noticed in case of HIV-1 gag expression vector HXB2 pGag-EGFP.
APH-2 overexpression additionally inhibited the power of HIV-1 Tat to transactivate the HIV-1 LTR-driven expression of luciferase. Moreover, the introduction of mutations within the IXXLL motif on the N-terminal area of APH-2 reverted the inhibitory impact on HIV-1 Tat-mediated transcription, suggesting the attainable function of this motif in the direction of the downregulation of Tat-mediated transactivation.
General, these findings point out that the HTLV-2 APH-2 could have an effect on the HIV-1 replication at a number of ranges by (a) inhibiting the Tat-mediated transactivation and (b) hampering the virus launch by affecting the mobile gag expression.
An Epitope Platform for Protected and Efficient HTLV-1-Immunization: Potential Purposes for mRNA and Peptide-Based mostly Vaccines
Human T-cell lymphotropic virus kind 1 (HTLV-1) an infection impacts hundreds of thousands of people worldwide and might result in extreme leukemia, myelopathy/tropical spastic paraparesis, and quite a few different issues.
Pursuing a protected and efficient immunotherapeutic method, we in contrast the viral polyprotein and the human proteome with a sliding window method with a view to determine oligopeptide sequences distinctive to the virus. The immunological relevance of the viral distinctive oligopeptides was assessed by looking out them within the immune epitope database (IEDB). We discovered that HTLV-1 has 15 peptide stretches every consisting of uniquely viral non-human pentapeptides that are ideally suited candidate for a protected and efficient anti-HTLV-1 vaccine.
HTLV-1 gp21 (Recombinant) |
|
22060225-1 |
Bio-WORLD |
100 µg |
EUR 344.89 |
Recombinant HTLV-1 gp21 |
|
MBS142626-01mg |
MyBiosource |
0.1mg |
EUR 330 |
Recombinant HTLV-1 gp21 |
|
MBS142626-05mg |
MyBiosource |
0.5mg |
EUR 825 |
Recombinant HTLV-1 gp21 |
|
MBS142626-1mg |
MyBiosource |
1mg |
EUR 1515 |
Recombinant HTLV-1 gp21 |
|
MBS142626-5x1mg |
MyBiosource |
5x1mg |
EUR 6485 |
HTLV I gp21 Protein |
|
abx060598-100g |
Abbexa |
100 µg |
Ask for price |
HTLV I gp21 Protein |
|
abx060598-100ug |
Abbexa |
100 ug |
EUR 811.2 |
|
|
HTLV I gp21 Protein |
|
abx060598-10g |
Abbexa |
10 µg |
EUR 937.5 |
HTLV I gp21 Protein |
|
abx060598-50g |
Abbexa |
50 µg |
Ask for price |
HTLV-1 gp21 recombinant protein |
|
00700-V |
Virogen |
1 MG |
EUR 850 |
HTLV-1 gp21 recombinant protein |
|
00700-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
|
|
Description: HTLV-1 gp21 recombinant protein |
HTLV-1 gp21 recombinant protein |
|
00700-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
|
|
Description: HTLV-1 gp21 recombinant protein |
HTLV-1 gp21 recombinant protein |
|
00700-V-100ugvial |
Virogen |
100 ug/vial |
EUR 150 |
|
|
|
Description: HTLV-1 gp21 recombinant protein |
HTLV-1 gp21 recombinant protein |
|
MBS485128-01mg |
MyBiosource |
0.1mg |
EUR 300 |
HTLV-1 gp21 recombinant protein |
|
MBS485128-1mg |
MyBiosource |
1mg |
EUR 1300 |
HTLV-1 gp21 recombinant protein |
|
MBS485128-5x1mg |
MyBiosource |
5x1mg |
EUR 5795 |
HTLV-1 gp21 recombinant protein |
|
00700-V-01 |
Virogen |
100 µg |
Ask for price |
HTLV-1 gp21 recombinant protein |
|
00700-V-02 |
Virogen |
1 mg |
Ask for price |
HTLV-I gp21 Recombinant |
|
MBS318676-01mg |
MyBiosource |
0.1mg |
EUR 740 |
HTLV-I gp21 Recombinant |
|
MBS318676-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3160 |
Recombinant HTLV-1 gp21 Antigen, GST-tagged |
|
HTL-250 |
Creative BioMart |
1 vial |
EUR 798.4 |
|
|
|
Description: Protein |
Recombinant HTLV gp21 Protein (Coating) [2B3A] |
|
VAng-Lsx0306-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: HTLV gp21 Antigen [2B3A], Recombinant antigen. |
Recombinant HTLV gp21 Protein (Detection) [PV112] |
|
VAng-Lsx0307-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: HTLV gp21 Antigen [PV112], Recombinant antigen. |
Recombinant HIV HTLV-1 gp21 Protein, GST, E.coli-1mg |
|
QP12354-1mg |
EnQuireBio |
1mg |
EUR 1513.2 |
Recombinant HIV HTLV-1 gp21 Protein, GST, E.coli-100ug |
|
QP12354-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant HIV HTLV-1 gp21 Protein, GST, E.coli-500ug |
|
QP12354-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
HTLV-1 gp21, gp46, Recombinant (Human T Cell Leukemia Virus) |
|
MBS636428-01mg |
MyBiosource |
0.1mg |
EUR 540 |
HTLV-1 gp21, gp46, Recombinant (Human T Cell Leukemia Virus) |
|
MBS636428-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2275 |
Recombinant HTLV-1 gp21 and gp46 mosaic Antigen, GST-tagged |
|
HTL-252 |
Creative BioMart |
1 vial |
EUR 798.4 |
|
|
|
Description: Protein |
Recombinant HTLV-I Gp21 (a.a. 351-404), GST Tagged |
|
DAG443 |
Creative Diagnostics |
100ug |
EUR 627.38 |
|
|
|
Description: Recombinant |
HTLV-1 gp46 |
|
hiv-142 |
ProSpec Tany |
100µg |
EUR 165 |
|
Description: Recombinant HTLV-1 gp46 |
HTLV1 gp21 protein |
|
MBS537739-01mg |
MyBiosource |
0.1mg |
EUR 715 |
HTLV1 gp21 protein |
|
MBS537739-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3075 |
HTLV1 gp21 protein |
|
MBS836113-01mg |
MyBiosource |
0.1mg |
EUR 750 |
HTLV1 gp21 protein |
|
MBS836113-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3145 |
HTLV1 gp21 protein (HRP) |
|
MBS836134-005mg |
MyBiosource |
0.05mg |
EUR 805 |
HTLV1 gp21 protein (HRP) |
|
MBS836134-5x005mg |
MyBiosource |
5x0.05mg |
EUR 3460 |
HTLV1 gp21 protein (FITC) |
|
MBS837038-005mg |
MyBiosource |
0.05mg |
EUR 415 |
HTLV1 gp21 protein (FITC) |
|
MBS837038-5x005mg |
MyBiosource |
5x0.05mg |
EUR 1720 |
HTLV-1 gp46 Protein |
|
20-abx260285 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
|
HTLV-1 gp46 Protein |
|
abx260285-20g |
Abbexa |
20 µg |
EUR 950 |
HTLV-1 gp46 Protein |
|
abx260285-5g |
Abbexa |
5 µg |
EUR 350 |
HTLV-1 gp46 (Recombinant) |
|
22060226-1 |
Bio-WORLD |
100 µg |
EUR 344.89 |
Recombinant HTLV-1 gp46 |
|
MBS142627-01mg |
MyBiosource |
0.1mg |
EUR 330 |
Recombinant HTLV-1 gp46 |
|
MBS142627-05mg |
MyBiosource |
0.5mg |
EUR 825 |
Recombinant HTLV-1 gp46 |
|
MBS142627-1mg |
MyBiosource |
1mg |
EUR 1515 |
Recombinant HTLV-1 gp46 |
|
MBS142627-5x1mg |
MyBiosource |
5x1mg |
EUR 6485 |
HTLV-1 gp46 recombinant protein |
|
00701-V |
Virogen |
1 MG |
EUR 850 |
HTLV-1 gp46 recombinant protein |
|
00701-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
|
|
Description: HTLV-1 gp46 recombinant protein |
HTLV-1 gp46 recombinant protein |
|
00701-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
|
|
Description: HTLV-1 gp46 recombinant protein |
HTLV-1 gp46 recombinant protein |
|
00701-V-100ugvial |
Virogen |
100 ug/vial |
EUR 150 |
|
Description: HTLV-1 gp46 recombinant protein |
HTLV-1 gp46 recombinant protein |
|
MBS485161-01mg |
MyBiosource |
0.1mg |
EUR 300 |
HTLV-1 gp46 recombinant protein |
|
MBS485161-1mg |
MyBiosource |
1mg |
EUR 1300 |
HTLV-1 gp46 recombinant protein |
|
MBS485161-5x1mg |
MyBiosource |
5x1mg |
EUR 5795 |
HTLV-1 gp46 recombinant protein |
|
00701-V-01 |
Virogen |
100 µg |
Ask for price |
HTLV-1 gp46 recombinant protein |
|
00701-V-02 |
Virogen |
1 mg |
Ask for price |
HTLV-1, gp21, Recombinant (Human T Lymphotropic Virus I, Human T-lymphotropic Virus 1, HTLV1, Human T Cell Leukemia Virus) |
|
MBS636303-01mg |
MyBiosource |
0.1mg |
EUR 715 |
HTLV-1, gp21, Recombinant (Human T Lymphotropic Virus I, Human T-lymphotropic Virus 1, HTLV1, Human T Cell Leukemia Virus) |
|
MBS636303-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3075 |
HTLV I gp46 Protein |
|
abx060599-100g |
Abbexa |
100 µg |
Ask for price |
HTLV I gp46 Protein |
|
abx060599-100ug |
Abbexa |
100 ug |
EUR 811.2 |
|
|
HTLV I gp46 Protein |
|
abx060599-10g |
Abbexa |
10 µg |
EUR 937.5 |
HTLV I gp46 Protein |
|
abx060599-50g |
Abbexa |
50 µg |
Ask for price |
Recombinant HTLV-1 gp46 protein, His-tagged |
|
GB46-01VH |
Creative BioMart |
100ug |
EUR 476.8 |
|
|
|
Description: Store it under sterile conditions at -20 to -80 ºC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
HTLV-I gp46 Recombinant |
|
MBS318640-01mg |
MyBiosource |
0.1mg |
EUR 740 |
HTLV-I gp46 Recombinant |
|
MBS318640-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3160 |
Recombinant HTLV-1 gp46 mosaic Antigen, His-tagged |
|
HTL-251 |
Creative BioMart |
1 vial |
EUR 798.4 |
|
|
|
Description: Protein |
HTLV-I gp46 Mosaic Recombinant |
|
rAP-5385 |
Angio Proteomie |
Inquiry |
Ask for price |
Recombinant HIV HTLV-1 gp46 mosaic Protein, Untagged, E.coli-1mg |
|
QP12355-1mg |
EnQuireBio |
1mg |
EUR 1513.2 |
Recombinant HIV HTLV-1 gp46 mosaic Protein, Untagged, E.coli-100ug |
|
QP12355-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant HIV HTLV-1 gp46 mosaic Protein, Untagged, E.coli-500ug |
|
QP12355-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
HTLV-1 TAX |
|
ant-290 |
ProSpec Tany |
0.5mg |
EUR 275 |
|
Description: Mouse Anti HTLV-1 TAX |
HTLV-1 p24 |
|
hiv-003 |
ProSpec Tany |
100µg |
EUR 165 |
|
Description: Recombinant HTLV-1 p24 |
HTLV-1 p24c |
|
hiv-108 |
ProSpec Tany |
100µg |
EUR 165 |
|
Description: Recombinant HTLV-1 p24 Core |
HTLV-1 Mosaic |
|
hiv-144 |
ProSpec Tany |
100µg |
EUR 165 |
|
Description: Recombinant HTLV-1 Mosaic |
HTLV-1 Envelope |
|
hiv-107 |
ProSpec Tany |
100µg |
EUR 165 |
|
Description: Recombinant HTLV-1 Envelope |
HIV-1 (HTLV-3) |
|
MBS324132-5x1mL |
MyBiosource |
5x1mL |
EUR 1465 |
HIV-1 (HTLV-3) |
|
MBS324133-5x1mL |
MyBiosource |
5x1mL |
EUR 1375 |
HIV-1 (HTLV-3) |
|
MBS324130-5x1mL |
MyBiosource |
5x1mL |
EUR 1320 |
HIV-1 (HTLV-3) |
|
MBS324131-5x1mL |
MyBiosource |
5x1mL |
EUR 1375 |
HTLV-1 p24 Protein |
|
20-abx260271 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
|
HTLV-1 p24 Protein |
|
abx260271-25g |
Abbexa |
25 µg |
EUR 950 |
HTLV-1 p24 Protein |
|
abx260271-5g |
Abbexa |
5 µg |
EUR 350 |
HTLV-1 TAX Antibody |
|
20-abx137064 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
HTLV-1 TAX Antibody |
|
abx137064-100tests |
Abbexa |
100 tests |
EUR 487.5 |
HTLV-1 Mosaic Protein |
|
20-abx260286 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
|
HTLV-1 Mosaic Protein |
|
abx260286-25g |
Abbexa |
25 µg |
EUR 950 |
HTLV-1 Mosaic Protein |
|
abx260286-5g |
Abbexa |
5 µg |
EUR 350 |
Recombinant HTLV-1 p24 |
|
MBS145392-01mg |
MyBiosource |
0.1mg |
EUR 330 |
Recombinant HTLV-1 p24 |
|
MBS145392-05mg |
MyBiosource |
0.5mg |
EUR 825 |
Recombinant HTLV-1 p24 |
|
MBS145392-1mg |
MyBiosource |
1mg |
EUR 1515 |
Recombinant HTLV-1 p24 |
|
MBS145392-5x1mg |
MyBiosource |
5x1mg |
EUR 6485 |
HTLV-1 Envelope Protein |
|
20-abx260142 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
|
HTLV-1 Envelope Protein |
|
abx260142-20g |
Abbexa |
20 µg |
EUR 950 |
HTLV-1 Envelope Protein |
|
abx260142-5g |
Abbexa |
5 µg |
EUR 350 |
Recombinant HTLV-1 Mosaic |
|
7-07773 |
CHI Scientific |
1000µg |
Ask for price |
Recombinant HTLV-1 Mosaic |
|
MBS142628-01mg |
MyBiosource |
0.1mg |
EUR 330 |
Recombinant HTLV-1 Mosaic |
|
MBS142628-05mg |
MyBiosource |
0.5mg |
EUR 825 |
Recombinant HTLV-1 Mosaic |
|
MBS142628-1mg |
MyBiosource |
1mg |
EUR 1515 |
Recombinant HTLV-1 Mosaic |
|
MBS142628-5x1mg |
MyBiosource |
5x1mg |
EUR 6485 |
HTLV-1, gp46, Recombinant (Human T Lymphotropic Virus I, Human T-lymphotropic Virus 1, HTLV1, Human T Cell Leukemia Virus) |
|
MBS636248-01mg |
MyBiosource |
0.1mg |
EUR 935 |
HTLV-1, gp46, Recombinant (Human T Lymphotropic Virus I, Human T-lymphotropic Virus 1, HTLV1, Human T Cell Leukemia Virus) |
|
MBS636248-5x01mg |
MyBiosource |
5x0.1mg |
EUR 4050 |
Recombinant HTLV-1 Protein |
|
VAng-Lsx0308-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: HTLV type 1, recombinant protein from E. coli. |
Recombinant HTLV-1 Envelope |
|
7-07753 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HTLV-1 Envelope |
|
7-07754 |
CHI Scientific |
500µg |
Ask for price |
Recombinant HTLV-1 Envelope |
|
7-07755 |
CHI Scientific |
1000µg |
Ask for price |
HTLV-1 Envelope (Recombinant) |
|
22060224-1 |
Bio-WORLD |
100 µg |
EUR 344.89 |
Recombinant HTLV-1 Envelope |
|
MBS142595-01mg |
MyBiosource |
0.1mg |
EUR 330 |
Recombinant HTLV-1 Envelope |
|
MBS142595-05mg |
MyBiosource |
0.5mg |
EUR 825 |
Recombinant HTLV-1 Envelope |
|
MBS142595-1mg |
MyBiosource |
1mg |
EUR 1260 |
Recombinant HTLV-1 Envelope |
|
MBS142595-5x1mg |
MyBiosource |
5x1mg |
EUR 5345 |
HTLV 1 ELISA Kit |
|
VArk-Lsx012 |
Creative Biolabs |
1 KIT |
Ask for price |
|
Description: Used for analyzing the presence of the human T-Cell lymphotropic viruses. |
HTLV-1 Tax (11-19) |
|
H-6096.0001 |
Bachem |
1.0mg |
EUR 138 |
|
Description: Sum Formula: C56H79N9O12; CAS# [141677-18-1] net |
HTLV-1 Tax (11-19) |
|
H-6096.0005 |
Bachem |
5.0mg |
EUR 441.6 |
|
Description: Sum Formula: C56H79N9O12; CAS# [141677-18-1] net |
HTLV-1 Tax9 (11-19) |
|
MBS8246638-10mg |
MyBiosource |
10mg |
EUR 465 |
HTLV-1 Tax9 (11-19) |
|
MBS8246638-1mg |
MyBiosource |
1mg |
EUR 205 |
HTLV-1 Tax9 (11-19) |
|
MBS8246638-5mg |
MyBiosource |
5mg |
EUR 335 |
HTLV-1 Tax9 (11-19) |
|
MBS8246638-5x10mg |
MyBiosource |
5x10mg |
EUR 2010 |
Rat HTLV-1 ELISA Kit |
|
ERH0319 |
Abclonal |
96Tests |
EUR 625.2 |
Goat HTLV-1 ELISA Kit |
|
EGTH0319 |
Abclonal |
96Tests |
EUR 625.2 |
Mouse Anti HTLV-1 TAX |
|
MBS140206-05mg |
MyBiosource |
0.5mg |
EUR 440 |
Mouse Anti HTLV-1 TAX |
|
MBS140206-1mg |
MyBiosource |
1mg |
EUR 600 |
Certainly, experimentally validated HTLV-1 epitopes, as retrieved from the IEDB, include peptide sequences additionally current in an unlimited variety of human proteins, thus doubtlessly instituting the premise for cross-reactions. We discovered a possible for cross-reactivity between the virus and the human proteome and described an epitope platform for use with a view to keep away from it, thus acquiring efficient, particular, and protected immunization. Potential benefits for mRNA and peptide-based vaccine formulations are mentioned.